SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

Fate Therapeutics Q1 EPS $(0.440) Misses $(0.390) Estimate, Sales $2.515M Beat $1.800M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.440) per share which missed the analyst consensus estimate of $(0.390) by 12.82 percent. This is a 46.67 percent decrease over losses of $(0.300) per share

Benzinga · 05/11/2020 20:17

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.440) per share which missed the analyst consensus estimate of $(0.390) by 12.82 percent. This is a 46.67 percent decrease over losses of $(0.300) per share from the same period last year. The company reported quarterly sales of $2.515 million which beat the analyst consensus estimate of $1.800 million by 39.72 percent. This is a 4.45 percent decrease over sales of $2.632 million the same period last year.